Programmed death-ligand 1 expression according to epidermal growth factor receptor mutation status in pretreated non-small cell lung cancer

BACKGROUND: Current clinical trials have suggested poorer efficacies of anti-programmed death-1 (PD-1)/PD-ligand 1 (PD-L1) immunotherapies for non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) mutations, implying lower PD-L1 expression in EGFR-mutant NSCLC than in...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Oncotarget
Hlavní autoři: Hata, Akito, Katakami, Nobuyuki, Nanjo, Shigeki, Okuda, Chiyuki, Kaji, Reiko, Masago, Katsuhiro, Fujita, Shiro, Yoshida, Hiroshi, Zama, Kota, Imai, Yukihiro, Hirata, Yukio
Médium: Artigo
Jazyk:Inglês
Vydáno: Impact Journals LLC 2017
Témata:
Research Paper
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5768364/
https://ncbi.nlm.nih.gov/pubmed/29371947
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.22837
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky